L Pickavance, P S Widdowson, P King, S Ishii, H Tanaka, G Williams
Index: Br. J. Pharmacol. 125(4) , 767-70, (1998)
Full Text: HTML
1. Young (6-week-old) pre-diabetic Zucker Diabetic Fatty (ZDF) rats displaying impaired glucose tolerance (IGT), moderate hyperglycaemia and hyperinsulinaemia were treated with the novel thiazolidinedione, MCC-555, for 28 days, during which time beta-cell failure and progression to overt diabetes occurs. 2. Treated ZDF rats exhibited consistently lower blood glucose levels than vehicle-treated diabetic controls, with a delayed rise and lower plateau levels. MCC-555 maintained plasma insulin levels throughout the treatment period, whereas these fell by 40% in untreated ZDF rats. 3. The rise in body weight was maintained in MCC-555-treated rats, whereas vehicle-treated rats exhibited blunted body weight gain after 8 weeks of age. Daily food intake was higher in diabetic, as compared to non-diabetic rats, but treatment did not modify food intake in diabetic rats. Water intake was lower in treated ZDF rats, concomitant with lowering of blood glucose. 4. The hyperinsulinaemic-euglycaemic clamp technique was applied to all rats after treatment to examine the effects of MCC-555 on insulin sensitivity. The glucose infusion rate to maintain normoglycaemia was lower in diabetic than in non-diabetic rats, demonstrating reduced glucose entry into insulin-sensitive tissues in diabetic rats. Increased glucose infusion rates were required to maintain euglycaemia in treated diabetic rats, demonstrating increased insulin sensitivity in these animals. 5. In conclusion, chronic MCC-555 treatment of young ZDF rats displaying IGT attenuates the development of overt diabetes through improved insulin sensitivity and maintenance of beta-cell function. MCC-555 may thus be beneficial in humans with IGT, to prevent or delay the progression of diabetes.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
netoglitazone
CAS:161600-01-7 |
C21H16FNO3S |
MCC-555-induced NAG-1 expression is mediated in part by KLF4...
2010-07-10 [Eur. J. Pharmacol. 637(1-3) , 30-7, (2010)] |
Chronic treatment with the thiazolidinedione, MCC-555, is as...
2003-04-01 [Int. J. Exp. Pathol. 84(2) , 83-9, (2003)] |
Activation of PPARgamma is not involved in butyrate-induced ...
2005-10-15 [Exp. Cell Res. 310(1) , 196-204, (2005)] |
Quantitative determination of MCC-555, a novel insulin sensi...
2006-05-01 [J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 835(1-2) , 35-9, (2006)] |
[KRP-297, MCC-555].
2001-11-01 [Nihon Rinsho. 59(11) , 2200-6, (2001)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved